Multiplexed and quantitative immunolabelling for cancer diagnostics using gold-silver alloy nanoprobes

使用金银合金纳米探针进行癌症诊断的多重定量免疫标记

• 批准号: 571982-2022
• 负责人: Meunier, MichelM
• 金额: $ 9.11万
• 依托单位: École Polytechnique de Montréal
• 依托单位国家: 加拿大
• 项目类别: Idea to Innovation
• 财政年份: 2022
• 资助国家: 加拿大
• 起止时间: 2022-01-01 至 2023-12-31
• 项目状态: 已结题
• 来源: https://www.nserc-crsng.gc.ca/ase-oro/Details-Detailles_eng.asp?id=754571
• 关键词: Multiplexed; quantitative; immunolabelling; cancer; diagnostics

This proposal aims to introduce new immunolabelling probes based on gold-silver alloy nanoparticles (ANPs) for application in clinical pathology imaging of cancer. Such probes open the possibility to perform quantitative and multiplexed analysis, thus overcoming the important limitations of present immunolabelling techniques. These ANPs can be identified by their spectral signature (colour), enabling multiplexed cell labelling and identification. The ANP labels are stable and bright, and upon modification to bind a specific target, they can enable the biomarker quantification. Such quantification is highly valuable for pathologists who must precisely determine the cancer type and then select the most efficient treatment for the patient, as is needed for immunotherapy. We will mediate the maturation of our research to obtain a robust technology and demonstrate the advantages of antibody-functionalized ANPs as probes for the quantification of PD-L1, a protein biomarker of non-small cell lung cancer. Our approach ought to yield a much higher immunotherapy treatment success rate than is currently available by tailoring treatment specifically toward a patient. The target market segments for this technology are the reagents for immunolabelling (expected to reach USD $2.6 billion in 2026) and the global market for immunotherapy (USD $150 billion). A patent for our ANPs and related process has already been issued (US Patent 10,239,122 (2019)). Moreover, this project also shows potential for the development of new patents for the complete imaging system. Highly respected pathologists, who are potential users in the health sector, have confirmed the value of our new technology and will test it in their own clinical activities. To move our project to commercialization for the synthesis of ANPs, their functionalization, production of the optical imaging setup, and software analysis, the creation of a start-up at Polytechnique Montréal is being considered. Roche, an international leader in in vitro diagnostics, sees tremendous potential in this technology to transform cancer diagnosis and has expressed support for our PD-L1 detection strategy for partnership development.

该建议旨在基于金丝合金纳米颗粒（ANP）引入新的免疫标记问题，以应用于癌症的临床病理成像。此类问题为执行定量和多重分析的可能性开辟了可能性，从而克服了当前免疫标记技术的重要局限性。这些ANP可以通过它们的光谱特征（颜色）来识别，从而实现多重细胞标记和识别。 ANP标签是稳定且明亮的，并且在修改以结合特定目标时，它们可以实现生物标志物定量。这种定量对于必须准确确定癌症类型然后为患者选择最有效治疗的病理学家非常有价值。我们将调解我们的研究成熟，以获得强大的技术，并证明抗体功能化ANP的优势是定量PD-L1的问题，PD-L1是非小细胞肺癌的蛋白质生物标志物。我们的免疫治疗成功率要高于目前通过专门针对患者的治疗而获得的方法要高得多的方法。该技术的目标市场细分是免疫标签的试剂（预计在2026年将达到26亿美元）和全球免疫疗法市场（1500亿美元）。我们的ANP和相关过程的专利已经颁发（美国专利10,239,122（2019））。此外，该项目还显示了为完整成像系统开发新专利的潜力。备受推崇的病理学家是卫生部门的潜在用户，已经确认了我们新技术的价值，并将在自己的临床活动中对其进行测试。为了将我们的项目转移到合成ANP的商业化，其功能化，光学成像设置的产生和软件分析，正在考虑在PolytechniqueMontréal创建启动。罗氏（Roche）是体外诊断的国际领导者，他认为这项技术改变了癌症诊断的潜力，并表示支持我们的PD-L1检测策略以开发伙伴关系。